One Year Later: What the FDA’s MDMA Rejection Taught Us—and Where Psychedelic Medicine Goes Next

A Sobering Milestone in Psychedelic Medicine

On August 9, 2024, the U.S. Food and Drug Administration issued a Complete Response Letter (CRL) rejecting Lykos Therapeutics’ New Drug Application (NDA) for MDMA-assisted therapy in treating PTSD. The rejection stung—not only for the nearly 70% of trial participants whose PTSD remitted—but also for the tens of thousands advocating for this groundbreaking treatment.

What went wrong? A host of key criticisms centered around:

• Data integrity and trial design—notably functional unblinding, where participants (and possibly clinicians) could guess who received MDMA versus placebo, introducing bias.
• Safety concerns, especially around insufficient cardiovascular monitoring and unclear abuse potential.
• Ethical mishaps and misconduct, including a deeply troubling sexual abuse case involving trial staff, which led to retraction of several journal articles.
• Lack of diversity in participants and concerns about the generalizability of results.

In June 2024, the FDA’s Psychopharmacologic Drugs Advisory Committee voted 9–2 that available data didn’t prove effectiveness, and 10–1 that benefits did not outweigh risks.

One Year Later: Reflection and Reality Check

Psychedelic Alpha’s comprehensive retrospective dives deep, featuring interviews with key figures including MAPS founder Rick Doblin, ex–Lykos insiders, FDA advisory members, critics, academics, and investors.

Lessons Learned:

• Designing with rigor: Future trials must address unblinding with more creative controls (like active comparators), strengthen safety monitoring, diversify participants, and tighten reporting standards.
• Independent oversight: Governance structures should mitigate conflicts of interest, particularly when advocacy and business overlap—as seen in the roles of MAPS/Lykos and Rick Doblin.
• Ethics first: The field needs robust safeguards against misconduct; especially crucial in highly vulnerable, suggestible therapeutic contexts.
• Advocacy matters: Critics like Psymposia played a role—but the FDA cited multiple structural and data concerns, not just external pressure.

What’s Next for Psychedelic Medicine?

Despite the setback, momentum continues:

• Regulatory shifts: New leadership—like FDA Commissioner Marty Makary and HHS secretary RFK Jr.—signal renewed openness to psychedelic research under the MAHA initiative, offering potential political and policy lifelines.
• Global interest: International dialogues and some jurisdictions (e.g., Australia) continue to explore or ease access to MDMA-based therapies.
• A crowded pipeline: Roughly 95 psychedelic compounds are currently in preclinical to Phase?3 development—litmus for how expansive and dynamic the field still is.
• Veteran-centered care: Despite FDA caution, organizations like the U.S. Department of Veterans Affairs are investing in PTSD and addiction-focused psychedelic therapy studies.

For Learn Euphoria Readers: Why It Matters

1. Science evolves through scrutiny—failures spur better design, not abandonment. The MDMA-AT setback is a critical pivot point, not a dead end.
2. Ethics underpins credibility—especially in medicine dealing with altered consciousness, where patients are uniquely vulnerable.
3. Leadership shapes the story—the interplay between activism, biotech, regulators, and political arenas continues to chart this field’s future.
4. the big picture endures—just because one therapy was rejected doesn’t mean the whole field will fall. Psychedelic medicine is on a broader ascent, albeit with rigorous tests ahead.

The FDA’s rejection of MDMA-assisted therapy one year ago was a setback—but not the finale. It was a call to refine, strengthen, and ethically ground the field. If we take these hard lessons seriously, psychedelics may yet offer real, lasting relief to those who need it most.